- Allergies11 product
- Anti Fungal33 products
- Anti Viral44 products
- Antibiotics1616 products
- Anxiety33 products
- Arthritis33 products
- Asthma55 products
- Blood Pressure66 products
- Cholesterol Lowering33 products
- Depression99 products
- Diabetes33 products
- Erectile Dysfunction44 products
- Gastrointestinal1313 products
- Hair Loss11 product
- Heart Disease33 products
- Herbals11 product
- Men's Health44 products
- Muscle Relaxant33 products
- Other2121 products
- Pain Relief1010 products
- Quit Smoking22 products
- Skincare88 products
- Sleep Aid33 products
- Weight Loss44 products
- Woman's Health1515 products
Beechwood Family Practice
Annagh Business Centre
Portadown
Craigavon BT62 3BE
+44 24 9496 6878
- The FDA has given fast track status to Pyxis’ drug candidate, PYX-201. This means that the review and approval process for this drug will be accelerated because it shows promise in treating a serious condition. This kind of designation is often granted to drugs that could potentially fulfill an unmet medical need. While the specific condition PYX-201 aims to treat wasn’t mentioned, similar fast-tracked drugs in the past have included names like Keytruda for cancer and Trikafta for cystic fibrosis.
- Regeneron is trying for a second time to get approval for its blood cancer treatment. If possible, could you include the names of some related medications in your explanation?
- Astellas, a pharmaceutical company, disagrees with European authorities about their drug Izervay, which is meant to treat geographic atrophy, a type of eye disease.
- After an earlier unsuccessful trial, EyePoint’s drug Duravyu shows promising results in treating diabetic macular edema (DME).
- How Helping Patients Can Make the Switch to the New Part D in 2025 Easier
